Nuvation Bio Inc. (NUVB) Stock Forecast
Data as of May 2, 2026Healthcare · Current price $4.50 (+1.01%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 21, 2026 | Leonid Timashev | RBC Capital | $12.00 | +167.0% |
| Jan 7, 2026 | Michael Yee | UBS | $10.00 | +122.5% |
| Dec 1, 2025 | Robert Burns | H.C. Wainwright | $10.00 | +122.5% |
| Apr 23, 2025 | Silvan Tuerkcan | JMP Securities | $6.00 | +33.5% |
| Sep 16, 2024 | Robert Burns | H.C. Wainwright | $7.00 | +55.7% |
| Apr 17, 2024 | Kennen MacKay | RBC Capital | $5.00 | +11.2% |
| Mar 28, 2024 | Robert Burns | H.C. Wainwright | $8.00 | +78.0% |
| Mar 27, 2024 | Michael Yee | Jefferies | $10.00 | +122.5% |
| Mar 26, 2024 | Kaveri Pohlman | BTIG | $5.00 | +11.2% |
Top Analysts Covering NUVB
NUVB vs Sector & Market
| Metric | NUVB | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.08 | 2.24 | 2.41 |
| Analyst Count | 13 | 8 | 18 |
| Target Upside | +175.9% | +1150.0% | +14.9% |
| P/E Ratio | -7.67 | 6.88 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $29M | $32M | $33M | 6 |
| 2026-09-30 | $34M | $42M | $45M | 4 |
| 2026-12-31 | $44M | $54M | $59M | 5 |
| 2027-03-31 | $63M | $78M | $84M | 3 |
| 2027-06-30 | $59M | $74M | $80M | 3 |
| 2027-09-30 | $62M | $77M | $83M | 3 |
| 2027-12-31 | $78M | $97M | $105M | 3 |
| 2028-12-31 | $356M | $407M | $466M | 7 |
| 2029-12-31 | $448M | $512M | $588M | 3 |
| 2030-12-31 | $670M | $766M | $879M | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-0.41 | $-0.17 | $-0.08 | 2 |
| 2026-09-30 | $-0.17 | $-0.15 | $-0.11 | 1 |
| 2026-12-31 | $-0.16 | $-0.15 | $-0.11 | 1 |
| 2027-03-31 | $-0.07 | $-0.07 | $-0.05 | 1 |
| 2027-06-30 | $-0.05 | $-0.05 | $-0.04 | 1 |
| 2027-09-30 | $-0.06 | $-0.05 | $-0.04 | 1 |
| 2027-12-31 | $0.01 | $0.01 | $0.01 | 1 |
| 2028-12-31 | $-0.30 | $-0.11 | $0.30 | 6 |
| 2029-12-31 | $0.05 | $0.06 | $0.07 | 4 |
| 2030-12-31 | $0.42 | $0.51 | $0.60 | 2 |
Frequently Asked Questions
What is the analyst consensus for NUVB?
The consensus among 13 analysts covering Nuvation Bio Inc. (NUVB) is Buy with an average price target of $12.40.
What is the highest price target for NUVB?
The highest price target for NUVB is $12.00, set by Leonid Timashev at RBC Capital on 2026-01-21.
What is the lowest price target for NUVB?
The lowest price target for NUVB is $5.00, set by Kaveri Pohlman at BTIG on 2024-03-26.
How many analysts cover NUVB?
13 analysts have issued ratings for Nuvation Bio Inc. in the past 12 months.
Is NUVB a buy or sell right now?
Based on 13 analyst ratings, NUVB has a consensus rating of Buy (2.08/5) with a +175.9% upside to the consensus target of $12.40.
What are the earnings estimates for NUVB?
Analysts estimate NUVB will report EPS of $-0.17 for the period ending 2026-06-30, with revenue estimated at $32M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.